Welcome to our dedicated page for TELEFLEX SEC filings (Ticker: TFX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Teleflex Incorporated filings document the regulatory record for a medical technology issuer with global product categories in anesthesia, emergency medicine, interventional cardiology and radiology, surgery, vascular access and urology. Periodic and current reports disclose operating results, GAAP and non-GAAP measures, revenue adjustments, foreign-currency effects, acquisition and integration items, divestiture-related costs, reserves and other factors affecting reported performance.
Teleflex 8-K filings also cover material events, executive and board transitions, compensation arrangements, shareholder communications, material agreements, capital-structure disclosures and clinical or regulatory matters when reported. Proxy materials disclose director elections, board committee matters, executive compensation, equity awards, pay-versus-performance information and shareholder voting items.
Teleflex Incorporated appointed Jason Weidman as its new President and Chief Executive Officer, effective June 8, 2026, succeeding interim CEO Stuart Randle, who will remain on the Board. The Board also expects to appoint Mr. Weidman as a director when he starts.
Mr. Weidman joins from Medtronic, where over nearly two decades he led large coronary, renal denervation, aortic, peripheral and venous businesses and oversaw global growth, product launches and acquisitions. His compensation package includes a $1 million base salary, a target annual bonus equal to 125% of salary and a $7 million annual equity award target beginning in 2027.
The offer includes a $7 million sign-on restricted stock grant and $1 million in stock options with multi‑year vesting, an up to $800,000 cash payment to replace forfeited incentives, relocation benefits and robust severance and change‑of‑control protections. In the company’s accompanying statement, the Chair highlighted Teleflex’s focus on core interventional and critical care markets and referenced an intended $1 billion share buyback and $800 million debt paydown following the close of pending sale transactions.
Teleflex Inc ownership update: Vanguard Capital Management reports beneficial ownership of 2,324,576 shares of Common Stock, representing 5.25% of the class. The filing states sole voting power for 340,752 shares and sole dispositive power for 2,324,576 shares. The filing attributes these holdings to Vanguard Capital Management and specified Vanguard affiliates and notes that some shares are held on behalf of Vanguard funds and managed accounts.
Teleflex Inc Schedule 13G: Vanguard Portfolio Management reports beneficial ownership of 2,458,623 shares of Teleflex common stock as of 03/31/2026, representing 5.56% of the class. The filing shows sole dispositive power for 2,458,623 shares and sole voting power for 20,440 shares. The form is signed by Ashley Grim on 04/29/2026.
Teleflex Inc corporate vice president Dominik Michal Reterski filed an initial ownership report, showing direct holdings of common stock, stock options and restricted stock units in Teleflex.
He holds 7,198 shares of common stock directly plus multiple stock option grants and RSU awards that vest over several years, contingent on continued service.
Teleflex Incorporated is asking stockholders to vote at its May 15, 2026 annual meeting on four items: electing seven directors for one-year terms, approving executive pay on an advisory basis, ratifying PricewaterhouseCoopers LLP as auditor, and handling other routine business.
The proxy details an actively refreshed, mostly independent board, including a new nominee, Michael J. Tokich, and an independent chair structure. It highlights Teleflex’s 2025 portfolio transformation, including acquiring BIOTRONIK’s Vascular Intervention business and signing agreements to sell the Acute Care, Interventional Urology and OEM units. These divestitures are expected to generate about $1.8 billion in after-tax proceeds, supporting a planned $1.0 billion share repurchase and $800 million of debt reduction.
The filing also explains governance practices, stockholder engagement, updated director compensation, and an executive pay program emphasizing performance-based incentives, stock ownership guidelines and clawback provisions. It notes CEO transitions, an ongoing search for a permanent chief executive, and design changes to performance stock units tied to absolute total shareholder return.
Teleflex Incorporated used this update to respond to Irenic Capital and restate its strategic plan. The company says it remains open to bona fide acquisition proposals but believes its current strategy will create more value. Teleflex highlights previously announced agreements to sell its Acute Care, Interventional Urology and OEM businesses, which are expected to close in the second half of 2026 and generate about $1.8 billion in after-tax net proceeds. It plans to use these proceeds for a $1.0 billion share repurchase and $800 million of debt reduction. Management also points to a multi-year restructuring plan targeting roughly $50 million in annual pre-tax cost savings by mid-2028, with some benefits beginning in 2026, as it focuses the company on higher-growth, higher-margin medical technology segments.
Teleflex Inc. Schedule 13G/A amendment shows The Vanguard Group reporting 0 shares beneficially owned of Teleflex common stock and 0% ownership following an internal realignment. The filing states certain Vanguard subsidiaries will report holdings separately in reliance on January 12, 1998.
The amendment is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Teleflex Incorporated outlines regulatory progress for two planned business divestitures. For its Original Equipment and Manufacturing and Development Services business, the Hart-Scott-Rodino waiting period expired at 11:59 p.m. Eastern Time on March 13, 2026, and completion is anticipated in the third quarter of 2026, subject to remaining regulatory approvals and other conditions.
For its Acute Care and Interventional Urology businesses, Teleflex and Intersurgical Limited received Federal Trade Commission Second Requests on March 11, 2026, extending the HSR waiting period until 30 days after each has substantially complied. This transaction is currently anticipated to close in the second half of 2026, subject to regulatory approvals and specified conditions. The two transactions are separate and may close independently.
Teleflex executive Daniel V. Logue, CVP, General Counsel & Secretary, reported a mix of equity grants and a tax-related share withholding. On March 3, 2026, he received a stock option award for 21,510 shares at $0.00 per share and two common stock awards of 3,262 and 6,591 shares under the Teleflex Incorporated 2023 Stock Incentive Plan. The footnotes state these restricted stock unit and option awards vest in stages between March 3, 2027 and March 3, 2030, subject to his continuous service.
On March 4, 2026, 131 common shares were disposed of at $119.18 per share to satisfy tax liabilities upon vesting of a restricted stock unit award, described as shares withheld rather than an open-market sale. After these transactions, he directly holds 24,652.888 common shares, and an additional 305.683 shares are held indirectly by a 401(k) trustee.